Improvements in quality of life associated with biphasic insulin aspart 30 in type 2 diabetes patients in China: results from the A1chieve® observational study

What Was Tested

The paper reports a study of Insulin Aspart and NPH Insulin (isophane), published as an observational study.

Descriptive statistics, paired t-test, and chi-square test were conducted and the linear ordinary least squares regression model was used to determine predictors for changes in EQ-5D score.

Why It Was Studied

Based on the 24-week, prospective, non-interventional, observational study, A1chieve®, the researchers investigated how health-related quality of life (HRQoL) changed, and the predictors of such changes, in Chinese people with type 2 diabetes mellitus (T2DM) after starting with, or switching to, biphasic insulin aspart 30 (BIAsp 30).

Who Took Part

The abstract describes 8,578 people taking part.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

In total, 8,578 people with T2DM starting treatment with, or switching to, BIAsp 30 were recruited from 130 urban hospitals in China.

HRQoL was assessed at baseline and 24 weeks using the EuroQol-5 dimensions (EQ-5D) questionnaire.

What Was Measured

PubMed files the paper under topics including Biphasic Insulins, China, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Insulin Aspart and Insulin, Isophane.

What This Means in Plain Language

This is an observational study of Insulin Aspart and NPH Insulin (isophane) in 8,578 people.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (Health and quality of life outcomes), a journal based in England.

More context: the Insulin Aspart compound page and the NPH Insulin (isophane) compound page, all human trials.